Pharvaris N.v. · NASDAQ:PHVS
Pharvaris — HAEi Regional Conference Americas 2026
5 slides from Pharvaris's conference presentation, October 2026
Slide 1: Oral Deucrictibant IR Capsule for On-Demand Treatment of HAE Attacks: Regional Subgroup Analysis
Oral Deucrictibant Immediate-Release Capsule for On-Demand Treatment of Hereditary Angioedema Attacks: Regional Subgroup Analysis From the Phase 3 RAPIDe-3 Trial Adil Adatia University of Alberta, Edmonton, AB, Canada Coauthors: Marc A. Riedl, Philip H. Li, Adil Adatia, Mauro Cancian, Marcin Stobiec
Slide 2: Conflicts of interest disclosure
Conflicts of interest disclosure I declare the following, real or perceived, conflicts of interest: Receipt of grants/research support: Astria, BioCryst, CSL Behring, Ionis Pharmaceuticals, KalVista, Octapharma, Pharvaris, and Takeda. Receipt of honoraria or consultation fees: Astria, BioCryst,
Slide 3: RAPIDe-3 study design and onset of symptom relief by region
Methods Results RAPIDe-3 study design Deucrictibant-treated attacks were shown to achieve onset of symptom Double-blind crossover treatment with relief faster than placebo-treated attacks in both subgroupsa,b 2 qualifying attack treatment periods North America Proportion of attacks achieving 100% De
Slide 4: Efficacy and safety endpoints by region
Results Efficacy endpoints Deucrictibant Placebo Safety endpoint Reduction in attack severitya,b The only event reported more than once within 3 days post-treatment was fatigue: a single Median 2.43 hours >12 hours event was reported by 2 participants, one of which was deemed unrelated to treatmen
Slide 5: Conclusions
Conclusions Results from the pivotal RAPIDe-3 trial for the treatment of attacks in HAE, including HAE-nC1INH, provide further evidence on the efficacy, safety, and tolerability of the orally administered B2R antagonist deucrictibant IR capsule. In this regional subgroup analysis, orally adminis